Supplementary Table 3 from Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab

Authors :: Clifford A. Hudis
Nathalie A. Lokker
Sunhee Kwon Ro
Alexander Starr
Rubina Qamar
Diana C. Medgyesy
Ellis Levine
Mark Keaton
Richard Emanuelson
Peter Eisenberg
Jeffrey J. Kirshner
Katherine Bell-McGuinn
Wei Wang
Hope S. Rugo
Edward J. Stepanski
Virginia Kaklamani
J. Thaddeus Beck
Claudine Isaacs
Grace Makari-Judson
Robert C. Hermann
Kurt W. Tauer
Lee S. Schwartzberg
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 55K, Study Drug Dosing (Safety Population)

Tools